Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Cancer Chemotherapy and Pharmacology
|
October 16, 2012
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
K N Chi, A Tolcher, P Lee, et al.
Investigational New Drugs
|
May 19, 2015
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
B J Eigl, S North, E Winquist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 24, 2020
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
D J Khalaf, I M Aragón, M Annala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
K N Chi, T Kheoh, C J Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
K Fizazi, K N Chi, N D Shore, et al.
Prostate Cancer and Prostatic Diseases
|
January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
H H Cheng, R Gulati, A Azad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer
S Halabi, S Dutta, C M Tangen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2023
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
S Chowdhury, A Bjartell, N Agarwal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 3, 2023
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
K N Chi, S Sandhu, M R Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)
H-M Lin, T Scheinberg, N Portman, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Cancer Chemotherapy and Pharmacology
|
October 16, 2012
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
K N Chi, A Tolcher, P Lee, et al.
Investigational New Drugs
|
May 19, 2015
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
B J Eigl, S North, E Winquist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 24, 2020
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
D J Khalaf, I M Aragón, M Annala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
K N Chi, T Kheoh, C J Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
K Fizazi, K N Chi, N D Shore, et al.
Prostate Cancer and Prostatic Diseases
|
January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
H H Cheng, R Gulati, A Azad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer
S Halabi, S Dutta, C M Tangen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2023
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
S Chowdhury, A Bjartell, N Agarwal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 3, 2023
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
K N Chi, S Sandhu, M R Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)
H-M Lin, T Scheinberg, N Portman, et al.
Page
of 4